Although many approaches have been developed for the diagnosis and treatment of BC, the 5-year survival rate of metastatic BC remains at 27% [1]. Cyclin-dependent kinases 4 and 6 (CDK4/6) play an important role in cell proliferation and are often dysregulated in BC, particularly in hormone-receptor (HR)-positive disease [2, 3]. This evidence concerns the gene NR4A1 and breast cancer.